225 related articles for article (PubMed ID: 37664028)
1. A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma.
Selim O; Song C; Kumar A; Phelan R; Singh A; Federman N
Front Oncol; 2023; 13():1244035. PubMed ID: 37664028
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
3. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
5. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma.
Phimmachanh M; Han JZR; O'Donnell YEI; Latham SL; Croucher DR
Front Cell Dev Biol; 2020; 8():578770. PubMed ID: 33117806
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
8. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Hedrick E; Crose L; Linardic CM; Safe S
Mol Cancer Ther; 2015 Sep; 14(9):2143-53. PubMed ID: 26162688
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Suraweera A; O'Byrne KJ; Richard DJ
Front Oncol; 2018; 8():92. PubMed ID: 29651407
[TBL] [Abstract][Full Text] [Related]
11. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Blattmann C; Oertel S; Ehemann V; Thiemann M; Huber PE; Bischof M; Witt O; Deubzer HE; Kulozik AE; Debus J; Weber KJ
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):237-45. PubMed ID: 20646843
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Mrakovcic M; Bohner L; Hanisch M; Fröhlich LF
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544838
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: Potential in cancer therapy.
Marks PA; Xu WS
J Cell Biochem; 2009 Jul; 107(4):600-8. PubMed ID: 19459166
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
